Evidence map›Paper›PMID 25320738›Full record

ArticleClinical and molecular hepatology2014

Chemotherapy induced liver abnormalities: an imaging perspective.

Ankush Sharma, Roozbeh Houshyar, Priya Bhosale, Joon-Il Choi, Rajesh Gulati, Chandana Lall

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and molecular hepatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 4 pooled it
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 4 syntheses or guidelines pooled it, 99 citations in OpenAlex.

  1. Pregnancy after cancer: FIGO Best practice advice.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025
    Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Effect of ursodeoxycholic acid and vitamin E in the prevention of liver injury from methotrexate in pediatric leukemia.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2018
    Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Ankush SharmaDepartment of Internal Medicine, University of California, Irvine, Orange, CA, USA.
Roozbeh HoushyarDepartment of Radiological Sciences, University of California, Irvine, Orange, CA, USA.
Priya BhosaleDepartment of Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Joon-Il ChoiDepartment of Radiology, Seoul St.Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Rajesh GulatiDepartment of Internal Medicine, University of California, Irvine, Orange, CA, USA.
Chandana LallDepartment of Radiological Sciences, University of California, Irvine, Orange, CA, USA.
University of California, Irvine · USCatholic University of Korea · KRThe University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treating patients undergoing chemotherapy who display findings of liver toxicity, requires a solid understanding of these medications. It is important for any clinician to have an index of suspicion for liver toxicity and be able to recognize it, even on imaging. Cancer chemotherapy has evolved, and newer medications that target cell biology have a different pattern of liver toxicity and may differ from the more traditional cytotoxic agents. There are several hepatic conditions that can result and keen clinical as well as radiographic recognition are paramount. Conditions such as sinusoidal obstructive syndrome, steatosis, and pseudocirrhosis are more commonly associated with chemotherapy. These conditions can display clinical signs of acute hepatitis, liver cirrhosis, and even liver failure. It is important to anticipate and recognize these adverse reactions and thus appropriate clinical action can be taken. Often times, patients with these liver manifestations can be managed with supportive therapies, and liver toxicity may resolve after discontinuation of chemotherapy.

Indexed as

AdultAgedAntibiotics, AntineoplasticAntimetabolites, AntineoplasticAntineoplastic AgentsAntineoplastic Agents, AlkylatingChemical and Drug Induced Liver InjuryEnzyme InhibitorsFatty LiverFemaleHumansImmunotherapyLiver CirrhosisLiver DiseasesMaleMiddle AgedAntibiotics, AntineoplasticAntimetabolites, AntineoplasticAntineoplastic AgentsAntineoplastic Agents, AlkylatingEnzyme InhibitorsChemotherapyHepatic NecrosisHepatic toxicityHepatitisPseudocirrhosisSteatosis

Identifiers

PMID25320738
PMCPMC4197183
OpenAlexW2041053691

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.